Syndax Pharmaceuticals, Inc. Operating Expenses
Syndax Pharmaceuticals, Inc. (SNDX) reported Operating Expenses of $112.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-06-30 was $112.78M, a 5.10% increase year-over-year.
- Syndax Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-03-31 was $99.07M, a 4.56% decline year-over-year.
- Syndax Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-12-31 was $131.28M, a 26.17% increase year-over-year.
- Syndax Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-09-30 was $103.30M, a 1.20% increase year-over-year.
- Syndax Pharmaceuticals, Inc. operating expenses for fiscal 2025 was $445.44M, a 22.59% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. operating expenses for fiscal 2024 was $363.35M, a 58.01% increase from fiscal 2023.
- Syndax Pharmaceuticals, Inc. operating expenses for fiscal 2023 was $229.95M, a 51.53% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. operating expenses for fiscal 2022 was $151.76M, a 33.72% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $112.78M 10-Q · filed 2026-08-04 | $211.85M 10-Q · filed 2026-08-04 | $343.13M derived: sum of 3 quarters · filed 2026-08-04 | $446.42M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $99.07M 10-Q · filed 2026-04-30 | $230.34M derived: sum of 2 quarters · filed 2026-04-30 | $333.64M derived: sum of 3 quarters · filed 2026-04-30 | $440.95M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $131.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $234.57M derived: sum of 2 quarters · filed 2026-02-26 | $341.88M derived: sum of 3 quarters · filed 2026-08-04 | $445.44M 10-K · filed 2026-02-26 |
| 2025-09-30 | $103.30M 10-Q · filed 2025-11-03 | $210.61M derived: sum of 2 quarters · filed 2026-08-04 | $314.16M 10-Q · filed 2025-11-03 | $418.45M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $107.31M 10-Q · filed 2026-08-04 | $210.86M 10-Q · filed 2026-08-04 | $315.15M derived: sum of 3 quarters · filed 2026-08-04 | $417.23M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $103.80M 10-Q · filed 2026-04-30 | $207.84M derived: sum of 2 quarters · filed 2026-04-30 | $309.92M derived: sum of 3 quarters · filed 2026-04-30 | $387.64M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $104.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $206.12M derived: sum of 2 quarters · filed 2026-02-26 | $283.84M derived: sum of 3 quarters · filed 2026-02-26 | $363.35M 10-K · filed 2026-02-26 |
| 2024-09-30 | $102.08M 10-Q · filed 2025-11-03 | $179.79M derived: sum of 2 quarters · filed 2025-11-03 | $259.31M 10-Q · filed 2025-11-03 | $337.21M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $77.72M 10-Q · filed 2025-08-04 | $157.23M 10-Q · filed 2025-08-04 | $235.13M derived: sum of 3 quarters · filed 2026-02-26 | $291.49M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $79.51M 10-Q · filed 2025-05-05 | $157.42M derived: sum of 2 quarters · filed 2026-02-26 | $213.77M derived: sum of 3 quarters · filed 2026-02-26 | $263.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $77.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $134.26M derived: sum of 2 quarters · filed 2026-02-26 | $183.94M derived: sum of 3 quarters · filed 2026-02-26 | $229.95M 10-K · filed 2026-02-26 |
| 2023-09-30 | $56.35M 10-Q · filed 2024-11-05 | $106.03M derived: sum of 2 quarters · filed 2024-11-05 | $152.05M 10-Q · filed 2024-11-05 | $194.08M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $49.68M 10-Q · filed 2024-08-01 | $95.69M 10-Q · filed 2024-08-01 | $137.73M derived: sum of 3 quarters · filed 2025-03-03 | $172.87M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $46.02M 10-Q · filed 2024-05-08 | $88.05M derived: sum of 2 quarters · filed 2025-03-03 | $123.19M derived: sum of 3 quarters · filed 2025-03-03 | $160.91M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $42.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $77.17M derived: sum of 2 quarters · filed 2025-03-03 | $114.90M derived: sum of 3 quarters · filed 2025-03-03 | $151.76M 10-K · filed 2025-03-03 |
| 2022-09-30 | $35.14M 10-Q · filed 2023-11-02 | $72.86M derived: sum of 2 quarters · filed 2023-11-02 | $109.72M 10-Q · filed 2023-11-02 | $140.55M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $37.72M 10-Q · filed 2023-08-03 | $74.58M 10-Q · filed 2023-08-03 | $105.41M derived: sum of 3 quarters · filed 2024-02-27 | $137.82M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $36.86M 10-Q · filed 2023-05-08 | $67.69M derived: sum of 2 quarters · filed 2024-02-27 | $100.09M derived: sum of 3 quarters · filed 2024-02-27 | $122.81M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $30.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $63.23M derived: sum of 2 quarters · filed 2024-02-27 | $85.95M derived: sum of 3 quarters · filed 2024-02-27 | $113.49M 10-K · filed 2024-02-27 |
| 2021-09-30 | $32.41M 10-Q · filed 2022-11-03 | $55.12M derived: sum of 2 quarters · filed 2022-11-03 | $82.66M 10-Q · filed 2022-11-03 | $102.90M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $22.71M 10-Q · filed 2022-08-08 | $50.26M 10-Q · filed 2022-08-08 | $70.50M derived: sum of 3 quarters · filed 2022-08-08 | $90.73M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $27.54M 10-Q · filed 2022-05-09 | $47.78M derived: sum of 2 quarters · filed 2022-05-09 | $68.01M derived: sum of 3 quarters · filed 2022-05-09 | $85.00M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $20.24M 10-K · filed 2021-03-12 | $40.47M derived: sum of 2 quarters · filed 2021-11-15 | $57.46M derived: sum of 3 quarters · filed 2021-11-15 | $72.94M 10-K · filed 2023-02-28 |
| 2020-09-30 | $20.23M 10-Q · filed 2021-11-15 | $37.22M derived: sum of 2 quarters · filed 2021-11-15 | $52.70M 10-Q · filed 2021-11-15 | $67.28M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $16.99M 10-Q · filed 2021-08-09 | $32.47M 10-Q · filed 2021-08-09 | $47.05M derived: sum of 3 quarters · filed 2021-08-09 | $60.58M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $15.48M 10-Q · filed 2021-05-11 | $30.06M derived: sum of 2 quarters · filed 2021-05-11 | $43.59M derived: sum of 3 quarters · filed 2021-05-11 | $59.34M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $14.59M 10-K · filed 2021-03-12 | $28.11M derived: sum of 2 quarters · filed 2021-03-12 | $43.87M derived: sum of 3 quarters · filed 2021-03-12 | $59.06M 10-K · filed 2022-03-01 |
| 2019-09-30 | $13.53M 10-K · filed 2021-03-12 | $29.28M derived: sum of 2 quarters · filed 2021-03-12 | $44.47M 10-Q · filed 2020-11-05 | $64.18M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $15.75M 10-K · filed 2021-03-12 | $30.94M 10-Q · filed 2020-08-06 | $50.66M derived: sum of 3 quarters · filed 2021-03-12 | $68.88M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $15.19M 10-K · filed 2021-03-12 | $34.90M derived: sum of 2 quarters · filed 2021-03-12 | $53.12M derived: sum of 3 quarters · filed 2021-03-12 | $72.45M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $19.71M 10-K · filed 2020-03-05 | $37.93M derived: sum of 2 quarters · filed 2020-03-05 | $57.26M derived: sum of 3 quarters · filed 2020-03-05 | $77.39M 10-K · filed 2021-03-12 |
| 2018-09-30 | $18.22M 10-K · filed 2020-03-05 | $37.55M derived: sum of 2 quarters · filed 2020-03-05 | $57.68M 10-Q · filed 2019-11-07 | $78.36M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | $19.33M 10-K · filed 2020-03-05 | $39.46M 10-Q · filed 2019-08-07 | $60.14M derived: sum of 3 quarters · filed 2020-03-05 | $75.89M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | $20.13M 10-K · filed 2020-03-05 | $40.81M derived: sum of 2 quarters · filed 2020-03-05 | $56.56M derived: sum of 3 quarters · filed 2020-03-05 | $70.71M derived: sum of 4 quarters · filed 2020-03-05 |
| 2017-12-31 | $20.68M 10-K · filed 2019-03-07 | $36.43M derived: sum of 2 quarters · filed 2019-03-07 | $50.58M derived: sum of 3 quarters · filed 2019-03-07 | $64.06M 10-K · filed 2020-03-05 |
| 2017-09-30 | $15.75M 10-K · filed 2019-03-07 | $29.90M derived: sum of 2 quarters · filed 2019-03-07 | $43.38M 10-Q · filed 2018-11-05 | $54.83M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $14.15M 10-K · filed 2019-03-07 | $27.63M 10-Q · filed 2018-08-08 | $39.08M derived: sum of 3 quarters · filed 2019-03-07 | $54.62M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $13.48M 10-K · filed 2019-03-07 | $24.93M derived: sum of 2 quarters · filed 2019-03-07 | $40.47M derived: sum of 3 quarters · filed 2019-03-07 | $49.41M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $11.45M 10-K · filed 2018-03-08 | $26.99M derived: sum of 2 quarters · filed 2018-03-08 | $35.93M derived: sum of 3 quarters · filed 2018-03-08 | $44.99M 10-K · filed 2019-03-07 |
| 2016-09-30 | $15.54M 10-K · filed 2018-03-08 | $24.48M derived: sum of 2 quarters · filed 2018-03-08 | $33.54M 10-Q · filed 2017-11-08 | $38.52M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $8.94M 10-K · filed 2018-03-08 | $18.00M 10-Q · filed 2017-08-10 | $22.98M derived: sum of 3 quarters · filed 2018-03-08 | $29.14M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $9.06M 10-K · filed 2018-03-08 | $14.04M derived: sum of 2 quarters · filed 2018-03-08 | $20.20M derived: sum of 3 quarters · filed 2018-03-08 | $25.76M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $4.98M 10-K · filed 2017-03-14 | $11.15M derived: sum of 2 quarters · filed 2017-03-14 | $16.71M derived: sum of 3 quarters · filed 2017-03-14 | $21.14M 10-K · filed 2018-03-08 |
| 2015-09-30 | $6.16M 10-K · filed 2017-03-14 | $11.72M derived: sum of 2 quarters · filed 2017-03-14 | $16.16M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $5.56M 10-K · filed 2017-03-14 | $9.99M 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $4.43M 10-K · filed 2017-03-14 | |||
| 2014-12-31 | $21.33M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |